Neuromodulation therapy for atrial fibrillation

Maham F Karatela(Duke University), Jonathan P. Piccini(Clinical Research Institute)
Heart Rhythm
August 18, 2022
10.1016/j.hrthm.2022.08.011
Cited by 22

Related Papers

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment
|European Heart Journal|2011|614
2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation
|EP Europace|2024|537
Screening for Atrial Fibrillation
|Circulation|2017|535
Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation
|Circulation|2012|499